Guest guest Posted August 26, 2008 Report Share Posted August 26, 2008 tired as always and lots of headaches ...gotta go see a neurologist lol Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_Central Date: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 26, 2008 Report Share Posted August 26, 2008 You drinkin' plenty of fluids and taking your Supplements, hon? From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 26, 2008 Report Share Posted August 26, 2008 what is that from? Ammonia?Jackie From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 Lots of fluids girl , no suppliments for me though..... my gi tract can't digest them well . [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 Could be from my hep c , porphyria, iron overload , my neck degeneration , or from my seizure disorder hahaha take yer pick [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 IM so very sorry Liz,, I sure wish there were something that I could do for you! you know I love ya!Jackie From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 Did you get your biopsy back yet, sweetie? From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 You can't even take Milk Thistle? From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 Stage 23/4 prmilinary grading from 2-4 [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 Nope my colitis flares up so bad it's aweful [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 Gf, you are messed up! Terry (hubby) has that, too.. From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 Can you put that in terms that non medical folks can comprehend, I don't like the sounds of that.. From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 It is painful and can lead to surgery eventually [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 stage almost 3( you might as well say stage 3) grade 4( some stage 2 regenerative cells present) [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 That doesn't sound happy, Liz..and no telling if you can treat again, I do wish they'd hurry with something better! From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 It has not made our home any happier, I can tell you, and the ultimate reason behind my stopping my own treatment early..Take care, only one of you... It is painful and can lead to surgery eventually Recent Activity 3 New Members 1 New PhotosVisit Your Group Yahoo! Health Asthma Triggers How you can identify them. Meditation and Lovingkindness A Yahoo! Group to share and learn. New business? Get new customers. List your web site in Yahoo! Search. .. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 sounds like it is moving along Liz but you havent reached stage 4 yet so there is still hope!Jackie From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 my mom was diagnosed with collitis a few months ago,, she says it hurts alotJackie From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 I think that is why they wanted me to get the biopsy , to see if I need to treat now or can wait longer [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 well it looks like you NEED to treat now before you reach stage 4 and ESLDJackie From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 When do you see your GI again? --- On Wed, 8/27/08, elizabethnv1 wrote I think that is why they wanted me to get the biopsy , to see if I need to treat now or can wait longer Recent Activity 3 New Members 1 New PhotosVisit Your Group Meditation and Lovingkindness A Yahoo! Group to share and learn. Yahoo! Health Achy Joint? Common arthritis myths debunked. New web site? Drive traffic now. Get your business on Yahoo! search. .. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 In a perfect world this would be so, but not everyone CAN treat, didn't they have to stop Liz last time? I know they did, her heart was acting up.. Hurry up Vertex! From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 Yeah , but it seems to be picking up speed . There are changes from last yrs bx [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 If I hit ESLD , it's pretty much it for me unless they find something that works for livers that damaged [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression By Liz Highleyman Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process. Warfarin Tablets The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression. The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 27, 2008 Report Share Posted August 27, 2008 I see hepatologist in Dec .. he will not be here til then Re: Liz.. Ot When do you see your GI again? --- On Wed, 8/27/08, elizabethnv1 <elizabethnv1earthlink (DOT) net> wrote I think that is why they wanted me to get the biopsy , to see if I need to treat now or can wait longer Recent Activity 3 New Members 1 New PhotosVisit Your Group Meditation and Lovingkindness A Yahoo! Group to share and learn. Yahoo! Health Achy Joint? Common arthritis myths debunked. New web site? Drive traffic now. Get your business on Yahoo! search. .. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.